UniSa - IRIS Institutional Research Information System

SELLERI, Carmine
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.541
AS - Asia 22.844
EU - Europa 12.334
SA - Sud America 1.722
Continente sconosciuto - Info sul continente non disponibili 742
AF - Africa 267
OC - Oceania 30
Totale 66.480
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.812
HK - Hong Kong 13.381
SG - Singapore 4.343
FI - Finlandia 4.165
IT - Italia 3.216
CN - Cina 2.177
BR - Brasile 1.316
VN - Vietnam 1.267
UA - Ucraina 1.209
DE - Germania 1.086
RU - Federazione Russa 771
IE - Irlanda 444
FR - Francia 404
CA - Canada 393
KR - Corea 340
TR - Turchia 307
IN - India 277
GB - Regno Unito 252
SE - Svezia 197
ES - Italia 186
BD - Bangladesh 183
AR - Argentina 168
JP - Giappone 112
MX - Messico 111
AT - Austria 108
IQ - Iraq 76
ZA - Sudafrica 75
NL - Olanda 66
PL - Polonia 64
PK - Pakistan 58
EC - Ecuador 57
ID - Indonesia 48
CO - Colombia 45
CZ - Repubblica Ceca 44
VE - Venezuela 44
MA - Marocco 37
UZ - Uzbekistan 34
CR - Costa Rica 32
JM - Giamaica 31
SA - Arabia Saudita 31
CL - Cile 30
MY - Malesia 30
ET - Etiopia 28
EU - Europa 28
HN - Honduras 26
PY - Paraguay 25
JO - Giordania 24
AU - Australia 23
EG - Egitto 23
PH - Filippine 22
GT - Guatemala 21
KE - Kenya 20
LT - Lituania 20
NI - Nicaragua 20
AE - Emirati Arabi Uniti 19
TN - Tunisia 19
PE - Perù 17
DO - Repubblica Dominicana 15
DZ - Algeria 14
KG - Kirghizistan 14
SC - Seychelles 14
KZ - Kazakistan 13
PR - Porto Rico 13
CH - Svizzera 12
IL - Israele 12
TT - Trinidad e Tobago 12
SV - El Salvador 11
UY - Uruguay 10
BE - Belgio 9
PA - Panama 9
AL - Albania 8
OM - Oman 8
AZ - Azerbaigian 7
AO - Angola 6
BB - Barbados 6
BO - Bolivia 6
HR - Croazia 6
HU - Ungheria 6
LB - Libano 6
LV - Lettonia 6
MD - Moldavia 6
NG - Nigeria 6
NP - Nepal 6
NZ - Nuova Zelanda 6
SY - Repubblica araba siriana 6
TH - Thailandia 6
BS - Bahamas 5
BZ - Belize 5
EE - Estonia 5
GP - Guadalupe 5
PS - Palestinian Territory 5
RS - Serbia 5
SN - Senegal 5
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
GR - Grecia 4
KW - Kuwait 4
LU - Lussemburgo 4
LY - Libia 4
MK - Macedonia 4
Totale 65.684
Salva come PNG Salva come JPEG
Città #
Hong Kong 13.339
Ann Arbor 4.703
Helsinki 3.835
Ashburn 2.627
San Jose 2.493
Woodbridge 2.449
Singapore 2.218
Jacksonville 1.469
Chandler 1.347
Milan 1.257
Houston 1.202
Dallas 1.185
Princeton 1.164
Wilmington 1.113
Council Bluffs 807
Beijing 476
Munich 451
Dong Ket 422
Dublin 419
Rome 365
Lauterbourg 345
New York 305
Ho Chi Minh City 293
The Dalles 284
Andover 283
São Paulo 282
Santa Clara 266
Nanjing 261
Los Angeles 251
Izmir 248
Boardman 246
Moscow 219
Salerno 213
Hanoi 194
Pellezzano 171
Naples 163
Düsseldorf 145
Valencia 120
Toronto 109
Fairfield 100
Chicago 96
Figino 96
Nuremberg 95
Shenyang 91
Turin 91
Brooklyn 90
Orem 90
Phoenix 88
Tokyo 87
Changsha 86
Nanchang 86
Jiaxing 81
Hebei 77
Montreal 74
Buffalo 72
Frankfurt am Main 69
Chennai 67
Washington 67
Atlanta 62
Turku 62
Warsaw 60
London 57
Denver 56
Redwood City 55
Seattle 55
Norwalk 49
Tianjin 49
Johannesburg 46
Mexico City 45
San Francisco 45
Vienna 45
Manchester 44
Pune 42
Boston 41
Columbus 41
Rio de Janeiro 41
Amsterdam 40
Cambridge 38
Dearborn 37
Brasília 36
Brno 36
Da Nang 36
Napoli 36
Stockholm 35
Haiphong 34
Mumbai 32
Tashkent 32
Philadelphia 31
Memphis 30
San Diego 29
Addis Ababa 28
Baghdad 28
Belo Horizonte 28
Charlotte 28
Shanghai 28
Guangzhou 25
Queens 24
Jinan 23
Lahore 23
The Bronx 23
Totale 50.977
Salva come PNG Salva come JPEG
Nome #
3D Biomimetic Scaffold for Growth Factor Controlled Delivery: An in-vitro study of Tenogenic events on Wharton’s Jelly Mesenchymal stem cells 2.040
3D in-vitro cultures of human bone marrow and Wharton’s jelly derived mesenchymal stromal cells show high chondrogenic potential 1.999
The metastasis-associated 67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell mobilization. 931
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study 911
Computer aided identification of small molecules interfering with the functional interaction of the urokinase receptor with fMLP receptors 882
Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case Series 725
Low-Density Granulocytes Are Decreased in Acute Myeloid Leukemia and in Myelodysplastic Syndromes with Negative Prognostic Factors 686
Endocrine disorders during the first year after autologous stem-cell transplant. 610
Development and Validation of a Reverse-Phase High-Performance Liquid Chromatography with Fluorescence Detection (RP-HPLC-FL) Method to Quantify Ruxolitinib in Plasma Samples 609
Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3. 595
Chondrogenic Commitment of human Bone Marrow Mesenchymal Stem Cells in a perfused, hTGF-β1-releasing PLGA microcarrier seeded, collagen hydrogel 589
2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis 532
67 KDA laminin receptor expression in human G-CSF mobilized CD34(+) peripheral blood stem cells correlates with their mobilization efficiency 510
Hemopoiesis and Immune Cell Perturbations during Venetoclax Plus Azacytidine Treatment in Acute Myeloid Leukemia 508
DECREASED LOW-DENSITY GRANULOCYTES AS POSSIBLE DIAGNOSTIC MARKERS OF MYELODYSPLASTIC SYNDROMES WITH EXCESS OF BLASTS 505
Aplastic anemia: Pathophysiology 499
Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia 486
Hodgkin Lymphoma and Hairy Cell Leukemia Arising from Chronic Lymphocytic Leukemia: Case Reports and Literature Review 426
Expression and function of the 67kDa laminin receptor in normal and acute leukemia cells 413
Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review 383
Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. 382
Post-therapy B regulatory cells might early predict relapse in Hodgkin lymphoma 372
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: Data from the Campania Rare Disease Registry 371
Immature forms of low density granulocytes are increased in acute myeloid leukemia and myelodysplastic syndromes 356
Involvement of soluble forms of receptor of the urokinase-type plasminogen activator (UPAR) in hematopoietic stem cell homing 351
WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes 346
Cell-free regenerative medicine: identifying the best source of mesenchymal stem cells for skin therapy in Systemic Sclerosis 345
A Rare Immune-Related Mesenteric and retroperitoneal serositis in a Multi-Refractory Hodgkin Lymphoma Patient Successfully Treated with Chylolymphostatic Surgery 336
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies 334
A novel approach to cell targeted complement inhibition in PNH: the human complement receptor 2/Factor H fusion protein TT30 prevents both hemolysis and upstream C3-opsonization of PNH erythrocytes 312
All Roads Lead to Interferon-γ: From Known to Untraveled Pathways in Acquired Aplastic Anemia 307
Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment 297
Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells 293
Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience 259
Contribution of peripheral blood mononuclear cells isolated by advanced filtration system to myogenesis of human bone marrow mesenchymal stem cells co-cultured with myoblasts 239
Giant plasma cells with multiple immature nuclei in a young woman with newly diagnosed multiple myeloma 231
Prolonged azacitidine treatment in the management of elderly patients with high risk myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia not eligible for standard intensive therapy 224
High incidence of cytomegalovirus reactivation in patients with lymphoma treated with bendamustine 224
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 224
The urokinase-receptor in infectious diseases. 223
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation 222
Bendamustine in combination with rituximab as first line therapy for patients with chronic lymphocytic leukemia (cll): a retrospective real practice italian multicentre study. 222
The cleaved form of soluble urokinase-receptor stimulates migration and mobilization of mouse CD34(+) cells in vitro and in vivo 219
Soluble forms of UPAR regulate adhesion, proliferation and survival of KG1 leukemic cells 216
CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples 216
A candidate complement inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria (PNH): preclinical data with tt30, a therapeutic that selectively blocks the complement alternative pathway. 214
Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens 211
Continuous maintenance therapy with alternate-day low dose lenalidomide in multiple myeloma patients after autologous stem cell transplantation 211
A novel crosstalk between calcium/calmodulin kinases II and IV regulates cell proliferation in myeloid leukemia cells 211
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 210
Autologous And Allogeneic Stem Cell Transplantation Is Associated With Long-Lasting Endocrine Disorders 210
Anaplastic CD30+ alk- (micro) lymphoma arising out of mediastinal Plasma Cell Castleman’s disease in immunocompetent patient treated by rituximab- dexametasone and continuous lenalidomide 209
Continuous alternate-day low dose lenalidomide in combination with low dose prednisone as frontline treatment for octogenarian newly diagnosed multiple myeloma patients 208
Bone marrow mesenchymal stem cells as a possible ruxolitinib reservoir in the bone marrow niche 208
A backwards evolution in a case of myeloproliferative disease 205
Interleukin-2 therapy in relapsed acute myelogenous leukemia. 201
67 KDa laminin receptor (67LR) expression and function in normal and acute myeloid leukemia CD34(+) cells 200
Accelerated and persistent bone loss after autologous and allogeneic stem cell transplantation 200
Lenalidomide-Mediated NK Cells Expansion In Elderly Multiple Myeloma Patients 197
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 197
Continuous maintenance therapy with alternate-day low dose lenalidomide in multiple myeloma patients after autologous stem cell transplantation increases the number of circulating natural killer cells 196
Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. 193
EFFICACY OF ALEMTUZUMAB PLUS EXTRACORPOREAL PHOTOPHERESIS IN ADVANCED STAGE SEZARY SYNDROME: A CASE REPORT 193
IgH assessment of non-Hodgkin lymphoma cells on FTA cards. 193
67 kDa laminin receptor: structure, function and role in cancer and infection. 192
Adjuvant treatment of diabetic foot 192
Involvement of the urokinase receptor in the cross-talk between hematopoietic stem/progenitor cells and the bone marrow microenvironment. 192
Sirt-1 as a novel therapeutic target for improving nitric oxide release in heterozygous and homozygous patients for mthfr mutations 191
Bendamustine in combination with rituximab for elderly patients with aggressive B non hodgkin lymphoma not eligible for anthracycline-based therapy 187
Impact of cytokine gene polymorphisms in myelodysplastic syndromes (MDS) 186
Discovery of new small molecules targeting the vitronectin binding site of the urokinase receptor that block normal and leukemic cell migration 185
Prophylactic therapy with oral low-dose valgancyclovir in cytomegalovirus-positive allogeneic stem cell transplant recipients 184
Impact of cytokine gene polymorphism in aplastic anemia (AA) 183
Circulating T Regulatory Cells Are Persistently Reduced in Non-Severe Acquired Aplastic Anemia 181
Unresponsiveness to erythropoietin therapy in a case of Blackfan Diamond anemia. 181
Estrogen-progestin-replacement therapy in women after stem cell transplant 180
Prolonged low-dose lenalidomide treatment increases the number of circulating natural killer cells in multiple mieloma patients 180
Fluorescent in situ hybridization with a Y probe in the follow up of sex-mismatch transplanted patients 179
A GITMO randomised trial in steroid refractory acute graft-versus-host disease: 6methylprednisolone with or without anti-thymocyte globulin 179
FAS antigen expression on normal and aplastic CD34+ cells. 178
Fas-mediated downmodulation of p210 BCR/ABL results in apoptosis of CD34+ cells of chronic myelogenous leukemia. 177
Role of the urokinase receptor in hematopoietic stem cell transplantation 176
67 KDA laminin receptor (67LR) in normal and neoplastic hematopoietic cells: is its targeting a feasible approach? 174
Effects of leptin and IGF-1 on bone mineral density in long-term survivors after allogeneic stem cell transplantation for hematological malignancies 173
The Role of B Regulatory Cells in the Immunological Escape of Tumor Cells in Hodgkin Lymphoma 173
A randomized trial of bone marrow (BM) versus peripheral blood (PB) allogeneic hemopoietic stem cell transplants (HSCT) in patients with myeloproliferative disorders. 172
Daily low-dose valgancyclovir is safe and effective CMV-reactivation prophylaxis in HLA-identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplantation 172
Expression of the 67 kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation 170
A novel chromosomal abnormality detected in a case of acute myelomonocytic leukemia. 170
Cyclosporin-A may improve in vitro circulating hematopoietic progenitors growth and affects CD4 cells expressing interferon-gamma of hypoplastic myelodysplastic patients. 169
Circulating T regulatory cells (TREG) are decreased in patients with aplastic anemia (AA). 168
Upar soluble forms and hematopoietic stem cell transplantion 168
Subcutaneous alemtuzumab is safe and effective for treatment of global or single-lineage immune-mediated marrow failure: a pilot study from the working party aplastic anaemia (WPSAA) 167
Paroxysmal nocturnal hemoglobinuria (PNH) in the eculizumab era: The bedside and beyond. 167
Interferon-alpha may modulate the balance between FAS-receptor and FAS-ligand expression on bone marrow chronic myeloid leukemia cells. 166
Previous occurrence of life-threatening abdominal infection is not a contraindication to marrow transplant. 165
High frequency of extramedullary relapse in patients transplanted for acute myeloid leukemia. 165
The role of FAS-mediated apoptosis in chronic myelogenous leukemia. 164
Determination of LTC-IC numbers in patients with myelodysplastic syndromes 164
Higher expression of Fas receptor on CD34+ cells of chronic myelogenous leukemia correlates with hematological response to IFN-alfa. 164
Totale 32.161
Salva come PNG Salva come JPEG
Categoria #
all - tutte 182.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 182.623
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.027 0 0 0 65 58 61 21 74 309 273 267 899
2022/20233.454 333 179 103 358 477 728 52 354 560 22 176 112
2023/20241.769 182 250 131 101 144 264 75 93 16 68 105 340
2024/20254.744 165 77 63 149 223 610 880 501 672 253 500 651
2025/202632.967 2.517 6.957 6.325 1.229 1.973 1.104 3.078 579 4.776 1.791 393 2.245
2026/20275.833 626 667 1.574 2.966 0 0 0 0 0 0 0 0
Totale 66.480